RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases

Annals of Surgery

Volumn 258, Issue 4, 2013, Pages 619-626

  Vauthey, Jean Nicolas ^a   Zimmitti, Giuseppe ^a   Kopetz, Scott E ^a   Shindoh, Junichi ^a   Chen, Su S ^a   Andreou, Andreas ^a   Curley, Steven A ^a   Aloia, Thomas A ^a   Maru, Dipen M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Colorectal liver metastases; Mutation; RAS

Indexed keywords

B RAF KINASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; RAS PROTEIN;

CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL FEATURE; COLORECTAL LIVER METASTASIS; CONFERENCE PAPER; FOLLOW UP; HUMAN; LIVER METASTASIS; LIVER RESECTION; LUNG METASTASIS; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PRIORITY JOURNAL; SOMATIC MUTATION; WILD TYPE;

COLORECTAL NEOPLASMS; FOLLOW-UP STUDIES; GTP PHOSPHOHYDROLASES; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MASS SPECTROMETRY; MEMBRANE PROTEINS; MUTATION; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84884493477     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3182a5025a     Document Type: Conference Paper

References (37)

1. Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27:3677-3683.
2. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230:309-318.
3. Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer. 1996;77:1254-1262.
4. Rees M, Tekkis PP, Welsh FK, et al. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg. 2008;247:125-135.
5. George B, Kopetz S. Predictive and prognostic markers in colorectal cancer. Curr Oncol Rep. 2011;13:206-215.
6. Kopetz S, Vauthey JN. Perioperative chemotherapy for resectable hepatic metastases. Lancet. 2008;371:963-965.
7. Blazer DG, III, Kishi Y, Maru DM, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008;26:5344-5351.
8. Maru DM, Kopetz S, Boonsirikamchai P, et al. Tumor thickness at the tumornormal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases. Am J Surg Pathol. 2010;34:1287-1294.
9. Brouquet A, Abdalla EK, Kopetz S, et al. High survival rate after two-stage resection of advanced colorectal livermetastases: response-based selection and complete resection define outcome. J Clin Oncol. 2011;29:1083-1090.
10. Chun YS, Vauthey JN, Boonsirikamchai P, et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA. 2009;302:2338-2344.
11. Shindoh J, Loyer EM, Kopetz S, et al. Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases. J Clin Oncol. 2012;30:4566-4572.
12. VanCutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment formetastatic colorectal cancer.NEngl JMed. 2009;360:1408-1417.
13. De Roock W, Claes B, Bernasconi D, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 2010;11:753-762.
14. Nash GM, Gimbel M, Shia J, et al. KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases. Ann Surg Oncol. 2010;17:572-578.
15. Andreou A, Kopetz S, Maru DM, et al. Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases. Ann Surg. 2012;256:642-650.
16. Tie J, Lipton L, Desai J, et al. KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer. Clin Cancer Res. 2011;17:1122-1130.
17. Kim MJ, Lee HS, Kim JH, et al. Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer. BMC Cancer. 2012;12:347.
18. Cejas P, Lopez-Gomez M, Aguayo C, et al. KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis. PLoS One. 2009;4:e8199.
19. Tran B, Kopetz S, Tie J, et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer. 2011;117:4623-4632.
20. Aloia TA, Zorzi D, Abdalla EK, et al. Two-surgeon technique for hepatic parenchymal transection of the noncirrhotic liver using saline-linked cautery and ultrasonic dissection. Ann Surg. 2005;242:172-177.
21. Pearce M, Ehrich M. Somatic mutation analysis in tumor samples using the Sequenom. In: MassARRAY R System. San Diego, CA: Sequenom, Inc
22. Gabriel S, Ziaugra L, Tabbaa D. SNP genotyping using the Sequenom MassARRAYiPLEX platform. Curr Protoc HumGenet. 2009;Chapter 2:Unit 2.12.
23. Thomas RK,BakerAC,Debiasi RM, et al. High-throughput oncogenemutation profiling in human cancer. Nat Genet. 2007;39:347-351.
24. Pearce M, Ehrich M. Somatic Mutation Analysis in Tumor Samples Using the Sequenom. MassARRAYRR System. Nat. Methods. 2010. http://www.nature.com/app- notes/nmeth/2010/101304/full/an7545.html.
25. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205-213.
26. MacConaill LE, Campbell CD, Kehoe SM, et al. Profiling critical cancer gene mutations in clinical tumor samples. PLoS One. 2009;4:e7887.
27. Andreou A, Aloia TA, Brouquet A, et al. Margin status remains an important determinant of survival after surgical resection of colorectal liver metastases in the era of modern chemotherapy. Ann Surg. 2013;257:1079-1088.
28. Stremitzer S, Stift J, Gruenberger B, et al. KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab. Br J Surg. 2012;99:1575-1582.
29. Maithel SK, Ginsberg MS, D'Amico F, et al. Natural history of patients with subcentimeter pulmonary nodules undergoing hepatic resection for metastatic colorectal cancer. J Am Coll Surg. 2010;210:31-38.
30. Kawamoto Y, Tsuchihara K, Yoshino T, et al. KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer. Br J Cancer. 2012;107:340-344.
31. Vauthey JN, Kopetz S, Aloia TA, et al. KRAS mutation in colorectal cancer metastases after adjuvant FOLFOX for the primary. Br J Cancer. 2012;107:1442-1443; author reply 1444.
32. Oudejans JJ, Slebos RJ, Zoetmulder FA, et al. Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver. Int J Cancer. 1991;49:875-879.
33. Etienne-Grimaldi MC, Formento JL, Francoual M, et al. K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin Cancer Res. 2008;14:4830-4835.
34. Santini D, Loupakis F, Vincenzi B, et al. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. Oncologist. 2008;13:1270-1275.
35. Italiano A, Hostein I, Soubeyran I, et al. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications. Ann Surg Oncol. 2010;17:1429-1434.
36. Knijn N, Mekenkamp LJ, Klomp M, et al. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer. 2011;104:1020-1026.
37. Vakiani E, Janakiraman M, Shen R, et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol. 2012;30:2956-2962.